Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182945 | 0.78 | SNCA (0.41) | SNCACA12CA2CA9CA1 | |
| SCHEMBL8535667 | 0.76 | SNCA (0.40) | SNCACA12CA2CA9CA1 | |
| SCHEMBL28883061 | 0.76 | SNCA (0.40) | SNCACA12CA2CA9CA1 | |
| SCHEMBL8694711 | 0.74 | GNAI3 (0.50) | SNCACA12CA2CA9CA1 | |
| SCHEMBL19503494 | 0.73 | GNAI3 (0.58) | SNCACA12CA2CA9GNAI3 | |
| SCHEMBL12821810 | 0.73 | SNCA (0.38) | SNCACA12CA2CA9CA1 | |
| SCHEMBL509603 | 0.72 | CA12 (0.38) | SNCACA12CA2CA9CA1 | |
| SCHEMBL1958727 | 0.71 | KDM1A (0.40) | CA12CA2CA9CA1 | |
| SCHEMBL6123168 | 0.71 | GNAI3 (0.52) | GNAI3GNAO1GNAI1 | |
| SCHEMBL19630043 | 0.70 | CA12 (0.37) | SNCACA12CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1420785-B1 | SUBSTITUTED INDENO [1,2-C]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2174659-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and uses thereof | Inotek Pharmaceuticals Corporation (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-2033645-A1 | Isoquinoline derivatives and methods of use thereof | Inotek Pharmaceuticals Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1603568-A4 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-7393955-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1722797-A4 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7268143-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1722797-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060019980-A1 | Methods for treating or preventing erectile dysfunction or urinary incontinence | INOTEK PHARMACEUTICAL, CORP. (US) | 2006-01-26 | — | — | US | disclosed |
| US-6956035-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050228007-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-10-13 | — | — | US | disclosed |
| WO-2005082368-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050049270-A1 | Isoquinoline derivatives and methods of use thereof | JAGTAP PRAKASH (US) | 2005-03-03 | — | — | US | disclosed |
| US-6828319-B2 | Antiinflamamtory agents; strokes; cardiovascular disorders | INOTEK PHARMACEUTICALS CORPORATION | 2004-12-07 | — | — | US | disclosed |
| WO-2004078712-A2 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| EP-1420785-A2 | SUBSTITUTED INDENO 1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2004-02-26 | — | — | US | disclosed |
| US-20030171392-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2003-09-11 | — | — | US | disclosed |
| WO-2003020700-A2 | SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228007-A1 | Isoquinoline derivatives and methods of use thereof | GLS, PINK1, PARK7 | SNCA 62/4885CA12 4830/4885CA2 4167/4885 |
| US-20080262016-A1 | ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | CYP3A7, CYP3A5, ABCG2 | SNCA 1360/4885CA12 4607/4885CA2 3914/4885 |
| US-20030171392-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof | CYP1B1, UGT1A1, CYP4B1 | SNCA 1022/4885CA12 4382/4885CA2 3670/4885 |
| US-20060019980-A1 | Methods for treating or preventing erectile dysfunction or urinary incontinence | PDE3A, PDE3B, PDE5A | SNCA 161/4885CA12 3290/4885CA2 2178/4885 |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | SNCA 1360/4885CA12 4607/4885CA2 3914/4885 |
| US-20050049270-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | SNCA 1360/4885CA12 4607/4885CA2 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.